← Back to Embecta Stock
Embecta (EMBC) News
San Francisco, California--(Newsfile Corp. - August 13, 2026) - Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business.
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important August 17, 2026 lead plaintiff deadline.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026. Embecta describes itself as a “leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866.
Important Information Regarding Section 20(a) Individual Liability Claims: Embecta's CEO and CFO Allegedly Certified Misleading Guidance That Cost Shareholders $5.35 Per Share NEW YORK, Aug. 13, 2026 /PRNewswire/ -- SueWallSt alerts investors in Embecta Corp. (NASDAQ: EMBC) of a pending securities class action naming two senior executives as individual defendants for their alleged role in disseminating misleading fiscal year 2026 guidance. Class Period: November 25, 2025 through May 4, 2026.
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
LOS ANGELES, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of EMBC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
New York, New York--(Newsfile Corp. - August 13, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC) on behalf of investors that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Embecta and have suffered losses, you may CLICK HERE to contact us.
Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBC PR Newswire
LOS ANGELES, Aug. 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of EMBC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
LOS ANGELES, Aug. 13, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. If you purchased Embecta Corp. securities, you may be entitled to compensation without payment of any out-of-pocket fees or costs.